Popular peptides right now

HGH 191AA is recombinant somatropin, the same 191-amino-acid growth hormone your pituitary makes. FDA-approved for growth hormone deficiency, it's used off-label for fat loss, recovery, and anti-aging at doses well above clinical guidelines. Quality varies wildly by source and manufacturer.

Retatrutide is a triple-agonist peptide (GLP-1, GIP, glucagon) that produced 28.7% weight loss in Phase 3 at 68 weeks. Not yet FDA approved. Among the largest trial weight-loss results reported so far, with liver fat reduction exceeding 80% in MASLD subgroups.

CJC-1295 plus Ipamorelin is the most popular pre-mixed GH secretagogue stack, valued for clean growth hormone release without cortisol or appetite spikes. Sleep improvements appear within two weeks. Body composition shifts follow by month two. No RCT exists for the combo, but individual-component data and thousands of community reports align closely.

Kisspeptin-10 triggers LH and testosterone release by activating the hypothalamic KISS1R receptor upstream of GnRH. Studied for fertility and post-TRT recovery, it requires cycling to avoid receptor desensitization. Community dosing runs 100 to 200 mcg subcutaneous daily or twice daily.

HGH (Somatropin) is FDA-approved recombinant growth hormone with clinical trial data spanning 15,809 patients. Rudman's foundational study showed 8.8% lean mass gain and 14.4% fat loss in six months. Pharma-grade pricing remains steep, but anti-aging protocols at 1 to 2 IU daily are the community standard for sleep, skin, and body composition.

AHK-Cu is a copper tripeptide with one published study showing hair follicle stimulation in vitro. Community use is mostly topical at 0.5 to 1% concentration. Injectable protocols exist but lack any direct scientific backing beyond structural similarity to GHK-Cu, which carries a far broader published evidence base.

The Wolverine Stack (BPC-157 + TB-500) combines two healing peptides in one pre-mixed vial. One retrospective report gave 4 of 16 knee pain patients the combination; 3 of 4 reported significant relief. Tens of thousands of community reports back up the science. No dedicated clinical trial exists yet, but this remains the most popular healing stack available.

Bromantane upregulates dopamine synthesis enzymes for calm, crash-free motivation. Approved in Russia for neurasthenia; an uncontrolled 728-patient study reported 90.8% CGI-I responders. Not FDA-approved; banned by WADA. Oral dosing at 50 to 100 mg daily, cycled 4 weeks on and 3 weeks off.

BPC-157 is the most popular healing peptide in the world, backed by 180+ PubMed papers and consistent user reports from tens of thousands of people. Community evidence for tendon and gut repair is hard to dismiss, though formal human trials remain limited to about 30 subjects total.

Dermorphin is a frog-derived opioid peptide with 30-40x morphine's analgesic potency. One 1985 human RCT showed superiority over morphine for postoperative pain; no further clinical trials exist. Likely classified as a Schedule I analog under US federal law. Research reference only, not for human use.

An opioid peptide with a grade D safety rating and one human trial, from 1985. Popular is not the same as safe.

PEG-MGF extends the muscle repair signal MGF from a 5-minute half-life to an estimated 48 to 72 hours. Community users report faster recovery and reduced soreness within weeks. All published research tested native MGF, not the PEGylated form. Research peptide only.

ARA-290 (cibinetide) activates the innate repair receptor to drive small nerve fiber regeneration without affecting red blood cell production. Phase 2b trials in sarcoidosis neuropathy showed a 23% increase in corneal nerve fiber area at the 4 mg dose. Research-only; no Phase 3 registered.

MOTS-c activates the same AMPK pathway triggered by exercise, making it one of the few true exercise mimetics. Preclinical data shows fat loss and insulin sensitization in mice; community users report improved endurance and glucose control within 2 to 4 weeks.

GHK-Cu modulates over 4,000 genes tied to collagen, wound repair, and aging. Community reports consistently describe firmer skin by week four and faster healing. No human injectable RCTs exist yet, but topical trials and decades of in vitro data back its core mechanisms. Available as subcutaneous injection or topical serum.

Tirzepatide targets both GIP and GLP-1 receptors, producing 20-22% body weight loss in important trials. FDA-approved as Zepbound (obesity) and Mounjaro (T2D). GI side effects during titration are the main limiting factor; a black box warning for thyroid tumors applies.

Cagrilintide activates amylin receptors, a pathway GLP-1 drugs miss entirely. REDEFINE 1 confirmed 11.5% weight loss as monotherapy and 20.4% combined with semaglutide at 68 weeks. CagriSema NDA is under FDA review. All standalone supply remains research-grade with no regulatory oversight.

MK-677 (Ibutamoren) is an oral growth hormone secretagogue backed by a 2-year RCT in healthy elderly adults. It raises IGF-1 40 to 60 percent without suppressing your natural GH axis. Appetite stimulation and insulin resistance are the main limitations. Research compound, not FDA approved.

ACE-031 traps myostatin to promote lean mass gains. Phase 1 showed 3.3% muscle increase from one injection, but vascular safety signals halted clinical development. Community protocols use doses far below trial levels. Quality verification is difficult for this recombinant fusion protein.

AOD-9604 targets fat cells through the beta-3 adrenergic receptor, a mechanism separate from appetite-based weight loss drugs. Phase IIa data showed 2.8 kg fat loss at 12 weeks. The Phase IIb trial failed its primary endpoint. Community users treat it as a mild recomposition stacking add-on, not a standalone solution.

Dihexa (PNB-0408) activates the HGF/c-Met pathway to promote synaptogenesis in animal models. No human trials exist. Two founding papers were retracted in 2025 for data fabrication. Community dosing runs 5 to 20 mg daily oral. Strictly experimental and unverified.

Semaglutide holds four FDA approvals for obesity, type 2 diabetes, and cardiovascular risk reduction. STEP 1 confirmed 14.9% mean weight loss at 68 weeks. The 7.2 mg high-dose version (March 2026) pushes that to 20.7%. GI side effects are real but manageable with slow titration.

Semax triples hippocampal BDNF in rodent models and is approved for stroke recovery in Russia. Short 10 to 20 day intranasal or subcutaneous cycles produce focus and memory benefits that persist weeks after stopping. No RCTs in healthy adults exist.

KLOW Blend packs BPC-157, TB-500, GHK-Cu, and KPV into one 80mg recovery vial. Community users report improved skin elasticity and gut comfort during GLP-1 therapy. No human trials exist for the combined formulation, but individual component data spans hundreds of preclinical studies.

SLU-PP-332 is a synthetic ERR agonist that mimics aerobic exercise at the gene level. Mouse data show 12% weight loss and 70% longer running times in 28 days. No human trials exist. Community protocols use 10 to 50 mg/day subcutaneous injection.

Tesamorelin is the only FDA-approved GHRH analog for visceral fat reduction, backed by Phase 3 data in 816 patients. Originally indicated for HIV lipodystrophy, it's now widely used off-label for belly fat and GH optimization. Antibody formation after extended use is the main drawback.

CJC-1295 (No DAC) triggers natural GH pulses with a 30-minute half-life. Paired with Ipamorelin in most protocols, it's the community's preferred GHRH analog for sleep, recovery, and body composition. No clinical trials of any kind exist for this specific form.

NA-Selank Amidate extends native Selank's anxiolytic and nootropic effects from minutes to hours through dual peptide stabilization. Approved in Russia under the parent formulation for GAD. No direct clinical trials exist for this specific modification. Research peptide only, not FDA approved.

NAD+ injectable protocols produce rapid cellular energy restoration and sirtuin activation. A 2019 IV infusion study confirmed 398% plasma elevation above baseline. Subcutaneous maintenance dosing at 100 to 250 mg twice weekly is the community standard for longevity use, though RCT evidence for wellness claims is still catching up.

BAM-15 is a selective mitochondrial uncoupler that reduced fat mass and improved insulin sensitivity in mice without raising body temperature. Oral and non-stimulant, it draws interest as a safer DNP alternative, though zero human trials exist and community doses fall far below allometric estimates.

SS-31 (elamipretide) earned FDA accelerated approval for Barth syndrome in September 2025, targeting mitochondrial cardiolipin to restore energy production. Community users run 2 to 10 mg daily for fatigue and longevity. Injection site reactions affect nearly everyone at some point.